PubMed Health⌕ Search

PubMed · 10933101

Endothelin-1 in stable bronchiectasis.

Abstract

Endothelin (ET)-1 has been suggested to promote neutrophil adhesion to endothelium, migration to inflamed areas, and release of elastase. ET-1 might therefore play a role in the pathogenesis of bronchiectasis, a chronic inflammatory and infective airway disease which is still poorly understood. Thirty five patients with stable bronchiectasis (20 females, mean age+/-SD 49.1+/-15.0 yrs) and 18 control subjects (8 females, 49.4+/-11.3 yrs) were recruited prospectively. The ET-1 levels in serum and sputum were measured by commercially available enzyme linked immunosorbent assay (ELISA) kits. Patients with Pseudomonas aeruginosa in their sputum had a significantly higher serum level of ET-1 (median 25.8, interquartile range 13-43.9 pg x mL(-1)) than patients without P. aeruginosa (0, 0-10.5 pg x mL(-1); p=0.0004) and healthy control subjects (4.6, 0-16.3 pg x mL(-1); p=0.002). However, patients with and without P. aeruginosa infection had no significant difference in sputum ET-1 level (p=0.15). There was no correlation between serum or sputum ET-1 levels with the serum and sputum levels of the interleukin (IL)-1beta, IL-8 and tumour necrosis factor (TNF)-alpha; the number of bronchiectasis lung lobes; and spirometry. Serum ET-1 level correlated with 24 h sputum volume for the bronchiectasis patients (r=0.51, p=0.002). The results, therefore, suggest a significant pathogenic role for endothelin-1 among Pseudomonas aeruginosa-infected patients with bronchiectasis. Further studies should be performed to evaluate the clinico-pathological correlation and expression of endothelin-1 in bronchiectasis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Zheng, G Tipoe, W K Lam, J C Ho, I Shum, G C Ooi, R Leung, K W Tsang. 2000. Endothelin-1 in stable bronchiectasis.. https://doi.org/10.1034/j.1399-3003.2000.16a26.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Paediatric bronchiectasis in Europe: what now and where next?

Bronchiectasis has been defined as the abnormal and permanent dilation of bronchi. It has a variety of causes and has traditionally been viewed as a condition that is irreversible, often progressive and associated with significant morbidity and mortality. In the past, patients had relatively advanced disease by the time the diagnosis was established. By using high-resolution computed tomography (HRCT) scanning of the chest, the potential now exists for the much earlier detection and treatment of children with lesser degrees of bronchial dilation and bronchial wall thickening than was previously possible. In some, the HRCT changes have been seen to improve or completely resolve. This calls into question exactly what now should be termed bronchiectasis and how the parents of children with such HRCT findings should be counselled about the likely prognosis and the necessary or desirable treatment options.

Bronchiectasis↗

Non-cystic-fibrosis bronchiectasis: a perspective from South America.

Nowadays, bronchiectasis tends to be considered a rare disease. This is really the case in developed countries, where good standards of living have been prevalent for many decades. But it might not be the case in the developing world, where better sanitary conditions are still needed. This article reviews non-cystic fibrosis bronchiectasis, emphasising differences between developed and developing countries. Diagnostic methods and therapeutic issues are discussed as is the Latin American experience of postviral bronchiectasis.

Bronchiectasis↗